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Introduction
What clinicians and patients need to know 
are the probabilities of obtaining certain 
outcomes from the different treatment 
options in the care environments avail-
able to them. For this they need evidence, 
quality information from research which 
is local, scientifically robust, current and 
matches as closely as possible to the clini-
cal status of patients. The problem is that 
international guidelines, and the medical 
community in general, inappropriately 
rank results of randomized trials (or me-
ta-analyses of randomized trials) as supe-
rior to all other research results with re-
spect to determining a patient’s best treat-
ment strategy. In the case of carotid artery 
stenosis management, this scientifical-
ly flawed view is a major reason why the 
field has become so biased towards using 
ineffective and harmful procedures and 
has lost track of what is best for patients.
Randomization and bias
In all the international guidelines on ca-
rotid stenosis we have  reviewed (A Sys-
tematic Review of Guidelines for the Man-
agement of Asymptomatic and Symptom-
atic Carotid Stenosis:  Abbott et al. manu-
script in preparation), it is implied or ex-
plicitly stated that randomized trial data 
are the best and most reliable evidence to 
guide treatment decisions in current, lo-
cal routine practice. Terms like ‘level A’ or 
‘class 1’ are used to indicate the superior-
ity of randomized trial data to the exclu-
sion of non-randomized data. The most 
important advantage of randomization 
(according to Wikipedia, 2015, http://
en.wikipedia.org/wiki/Randomized_con-
trolled_trial) is that “it minimizes alloca-
tion bias, balancing both known and un-
known prognostic factors, in the assign-
ment of treatments”; however, randomiza-
tion cannot always minimize treatment al-
location bias. Furthermore, this definition 
may be misinterpreted as meaning most, 
if not all, bias can be avoided by random-
ization; however, experience with carot-
id stenosis has clearly shown this is incor-
rect. Bias means “to present or hold a par-
tial perspective and often refusal to even 
consider the possible merits of alternative 
points of view” (Wikipedia, 2015, http://
en.wikipedia.org/wiki/Bias). Procedural 
bias with respect to carotid stenosis man-
agement has become entrenched and is 
evident in many ways, as discussed in this 
article.
How things should be: a world 
without procedural bias
If patients’ interests had always come first 
(and perhaps if we had been smarter) the 
randomized trials of medical treatment 
alone versus additional carotid endar-
terectomy (CEA) for asymptomatic pa-
tients (Veterans Affairs Cooperative Study 
[VACS], Asymptomatic Carotid Athero-
sclerosis Study [ACAS] and Asymptom-
atic Carotid Surgery Trial-1 [ACST] [18–
21]) would probably not have been done. 
Instead, we would have done quality non-
randomized   measurements of the risk of 
ipsilateral stroke in patients with asymp-
tomatic carotid stenosis (ACS) given the 
best available non-invasive medical treat-
ment alone. Medical treatment here refers 
to the encouragement of a healthy lifestyle 
and appropriate use of medication. Such 
measurements did not begin to appear 
in print until the mid-late 1980s and ear-
ly 1990s [1], well after these randomized 
procedural trials were planned and un-
derway. We could have discovered in the 
1980s and 1990s that the risk of ipsilater-
al stroke was lower than expected, proba-
bly not warranting the need for additional 
carotid procedures, especially in a routine 
practice where procedural outcomes are 
often not good enough to provide over-
all benefit or are not measured at all [5].
Even if an average annual ipsilater-
al stroke rate of approximately 2.3 %, de-
spite medical treatment alone (as in ACAS 
[18]), was seen as enough to justify CEA 
trials and then widespread routine prac-
tice use, CEA would not have been the 
standard of care for long. We would have 
kept measuring the impact of improving 
medical treatment and discovered much 
earlier than 2009 [1, 30] or 2013 [2, 3, 29, 
40] that stroke rates with medical treat-
ment alone fell below that of CEA pa-
tients treated in ACAS from 1995 (as soon 
as ACAS was published) and have contin-
ued to fall [1–3, 29, 30, 40]. In fact, ipsilat-
eral stroke rates are now so low with med-
ical treatment alone ( ≤ 0.5–1.0 % per year) 
that CEA is more likely to harm than help 
patients. Even if CEA complication rates 
were always zero (not possible), CEA is 
now likely to be an ineffective waste of re-
sources because at least 97.5 % of medical-
ly treated patients will not have a stroke 
due to the carotid lesion during the aver-
age 10-year life expectancy from diagno-
sis [6].
Regardless, we would have been mea-
suring 30-day rates of stroke and death 
whenever CEA was done and acted to ef-
fectively reduce risk of harm when out-
comes were below randomized trial stan-
dards. In addition, we would not have 
taken up routine CEA for asymptomatic 
women or men aged over 75–79 years be-
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cause evidence of a CEA stroke preven-
tion benefit has been inconclusive or ab-
sent [18–20].
In a world without a procedural bi-
as we would not have been advising for 
routine practice CAS for any patient 
with ACS or symptomatic carotid steno-
sis (SCS, carotid stenosis and ipsilateral 
stroke or transient ischemic attack) be-
cause CAS causes more strokes and peri-
procedural deaths (plus/minus periproce-
dural heart attacks) than CEA [4, 11], par-
ticularly in those with ipsilateral stroke or 
transient ischemic attack (TIA) within the 
previous 7 days (those most likely to ben-
efit from CEA) [33], women [23, 35] and 
patients older than 70 years, while a ben-
efit for patients aged < 70 years has not 
been established [11, 41]. This excessive 
CAS risk is not to be confused with (or 
hidden by) non-carotid artery associat-
ed causes of disability 1–5 years after CEA 
or CAS [10]. Furthermore, we would not 
be advising CAS for patients considered 
at high CEA risk due to vascular anato-
my or medical comorbidities because ma-
ny of these patients have a limited life ex-
pectancy (< 3–5 years) and are unlikely to 
live long enough to benefit, plus a proce-
dural benefit has never been demonstrat-
ed in such patients.
In a world without procedural bias we 
would not still be recommending CEA for 
generally fit but otherwise unselected pa-
tients with 50–99 % or 70–99 % SCS and 
ipsilateral stroke or TIA within the previ-
ous 3–6 months as long as the 30-day rate 
of stroke or death was < 6–7 % (A System-
atic Review of Guidelines for the Manage-
ment of Asymptomatic and Symptomatic 
Carotid Stenosis, Abbott et al. in prepara-
tion). Instead, we would have remeasured 
the impact of improving medical treat-
ment alone on recurrent stroke rate since 
symptomatic patients were recruited in-
to the randomized CEA trials 21–34 years 
ago [7, 17] and found a much lower stroke 
risk since then. This would have empha-
sized the need for much more selective 
CEA and much earlier used CEA as well 
as better procedural standards for patients 
with SCS than we have today.
So why have we finished up so far from 
where we should be, with international 
guidelines advocating CEA and/or CAS 
for just about any patients with >50 % ca-
rotid stenosis (sometimes for lesser de-
grees of stenosis [13, 39]) despite contrary 
or absent evidence (A Systematic Review 
of Guidelines for the Management of As-
ymptomatic and Symptomatic Carotid 
StenosisSystematic review of internation-
al carotid management guidelines, Abbott 
et al. in preparation)? A lot can be learned 
from an appreciation of biased design and 
interpretation of randomized carotid pro-
cedural trials, as outlined in this article.
Biased design of 
randomized trials
Randomizing to procedures 
before (or when) knowing 
the non-procedural risk
One should accurately know the risk of 
what is to be prevented using the simplest, 
least risky strategy before embarking on 
trials of expensive, dangerous and highly 
operator-dependent procedures. This did 
not happen for carotid stenosis. We are re-
inforcing past mistakes with more expen-
sive and slow randomized procedural tri-
als, such as the ‘Carotid Revascularization 
and Medical Management for Asymptom-
atic Carotid Stenosis Trial’(CREST-2) [25] 
of relatively unselected ACS patients (sim-
ilar to those in ACAS and ACST) before 
measuring the efficacy of current optimal 
medical treatment alone. However, worse, 
we now know these patients are most un-
likely to have an overall benefit from a ca-
rotid procedure. The effectiveness of cur-
rent optimal medical treatment alone 
would be most ethically and effectively 
measured by quality non-randomized tri-
als with built in risk stratification testing 
and validation [31]. Trials of carotid pro-
cedures should only be directed to those 
with a sufficiently high ipsilateral stroke 
risk despite current optimal medical treat-
ment alone, if they are reliably identified.
Randomizing to procedures only
Error was built upon error with the per-
formance of the randomized trials of 
CEA vs CAS in patients with ACS and 
SCS which lacked a medical treatment 
only comparison [4]. These later trials 
were based on the assumption that med-
ical treatment was simple, largely ineffec-
tive and would not change following the 
randomized trials of CEA versus medical 
treatment alone, mentioned above. This 
is an obvious bias in treatment allocation 
that randomization cannot correct: ran-
domizing patients only to procedures and 
concluding that a procedure is best.
Confuse the target population 
and exaggerate potential 
procedural benefits
Symptomatic patients have a higher stroke 
risk with medical treatment alone and are 
more likely to benefit from CEA than as-
ymptomatic patients [5]. With respect to 
carotid procedures (which target one ar-
tery), ACS is best defined as stenosis in 
patients with no past history of clinical-
ly recognized stroke or TIA in the corre-
sponding arterial territory. This is a dis-
tinct and easily identified clinical popu-
lation. The time by which the recurrent 
stroke risk in patients with symptomatic 
carotid stenosis reaches that of ACS is not 
known, particularly if patients are given 
current optimal medical treatment; how-
ever, results from the North American 
symptomatic carotid endarterectomy tri-
al (NASCET) suggest it may take at least 
2 years [7]. Therefore, inclusion of recent-
ly asymptomatic carotid stenosis patients 
(e.g. asymptomatic for only the last 3–6 
months as in some past procedural trials 
[14, 19, 20]) and extrapolation of results to 
truly asymptomatic patients will overesti-
mate a potential procedural benefit to the 
extent that such patients are included and 
their symptoms are recent.
Biased use of terminology
Medical treatment is the ongoing diagno-
sis of vascular disease risk factors and risk 
reduction by encouraging a healthy life-
style and appropriate use of medication. It 
is the best weapon we have to repair arter-
ies and reduce the risk of stroke and other 
complications of vascular disease. There-
fore, it adds to procedural bias when med-
ical treatment is referred to as ‘conserva-
tive,’ ‘control’ or ‘natural history’ therapy, 
as has been common in the past [1, 17, 19]. 
It is also biased to reserve more effective 
sounding terminology, such as ‘interven-
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tion’, ‘revascularization’ and ‘repair’ to pro-
cedures such as CEA or CAS [1, 35, 42].
Publish as soon as you find a 
statistically significant result
The 5-year stroke rates with CEA versus 
medical treatment alone in ACAS and 
ACST were estimates only, projected using 
Kaplan-Meier analyses from briefer actu-
al average follow-up durations. The me-
dian patient follow-up was just 2.7 years 
in ACAS [18] and the mean follow-up just 
3.4 years in ACST [20]. The assumption 
that trends will continue adds uncertainty. 
Significant differences in stroke rates with 
CEA versus medical treatment alone were 
not actually measured or observed in 
ACAS or ACST but based on projections. 
The results were published as soon as sta-
tistical significance (in contrast to clini-
cal significance) was found. The prima-
ry outcome comparisons in NASCET [7] 
and the MRC European carotid surgery 
trial (ECST) [17] were also 5-year stroke 
rates and were derived using Kaplan-Mei-
er analyses; however, the mean follow-up 
durations in these studies more close-
ly matched the primary outcome defini-
tions (5 [7] and 6 [17] years, respectively).
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Abstract
Background. Carotid artery procedures, 
such as surgery and stenting, although as-
sociated with significant risks and costs, are 
often recommended in guidelines which 
cite12- to 34-year-old randomized trial evi-
dence of benefit; however, these recommen-
dations exist although there is no evidence 
these procedures benefit patients who re-
ceive only current optimal medical treat-
ment  (encouragement of a healthy lifestyle 
and appropriate use of medication).
Objective. To examine whether bias exists in 
the use of randomized trial evidence and its 
impact on guideline recommendations.
Material and methods. Examples of how bi-
as underpins endorsement of carotid pro-
cedures for patients with asymptomatic or 
symptomatic carotid stenosis were sought 
from available literature. .
Results. Many forms of procedural bias were 
identified involving the need for randomized 
trials, and their design and interpretation. 
Fundamental problems included failure to 
first adequately measure outcomes with non-
invasive treatment alone, lack of appreciation 
of quality non-randomized trial measure-
ments of risk in determining need for ran-
domized trials and their applicability in rou-
tine practice, poor randomized trial methods 
with biased comparisons, inaccurate defini-
tions of target populations, confusion of effi-
cacy and safety outcomes,  too much reliance 
on statistical rather than clinical significance 
and biased use of terminology to make pro-
cedures sound more effective.
Conclusion. Procedural bias in design and 
interpretation of randomized trials has result-
ed in widespread loss of understanding of 
how to optimize outcomes in patients with 
carotid artery stenosis. Current guidelines re-
flect the cumulative impact of this bias and 
are an excellent starting point for efforts to 
improve prevention of stroke and other vas-
cular disease complications; however, there is 
also need for clinicians, policy makers, health 
service funding bodies, educators and the 
general public to assist.
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Bias bei der Verwendung randomisierter Studien für das Management der Karotisstenose
Zusammenfassung
Hintergrund. Häufig werden in Leitlinien 
mit dem Hinweis auf Evidenz aus randomi-
sierten Studien Interventionen an der A. caro-
tis empfohlen, etwa Operationen oder Stent-
einlagen, obwohl diese mit erheblichen Ri-
siken und Kosten einhergehen. Und solche 
Empfehlungen gibt es auch ohne Evidenz da-
für, dass Patienten, die rein internistisch opti-
mal behandelt werden, von diesen Interven-
tionen profitieren.
Ziel. Überprüft werden sollte ein mögliches 
Bias bei der Verwendung von Evidenz aus 
randomisierten Studien und sein Einfluss auf 
Leitlinienempfehlungen.
Material und Methoden. Beispiele werden 
vorgestellt, an denen sich zeigen lässt, wie 
ein Bias die Empfehlung für Interventionen 
bei asymptomatischer bzw. symptomatischer 
Karotisstenose untermauert.
Ergebnisse. Viele Formen von prozedu-
ralem Bias wurden identifiziert, sie bedingen 
den Bedarf für randomisierte Studien, De-
sign und Interpretation. Grundlegende Pro-
bleme waren u. a.: Es wurde nicht zunächst 
das Outcome nach nichtinvasiver Therapie al-
lein adäquat ausgewertet, bei der Festlegung 
der Notwendigkeit für randomisierte Studi-
en und bei der Anwendbarkeit in der Routine 
wurden qualitativ hochwertige, nichtrando-
misierte Studien zum Risiko nicht berücksich-
tigt, verwendet wurden mangelhafte Unter-
suchungsmethoden mit voreingenommenen 
Vergleichen, Zielkollektive wurden nicht rich-
tig definiert, Outcomes zur Effektivität wur-
den mit denen zur Sicherheit verwechselt, zu 
viel wurde entschieden aufgrund der statisti-
schen und zu wenig aufgrund der klinischen 
Bedeutung, und eine Bias-basierte Verwen-
dung der Terminologie ließ Interventionen 
effektiver scheinen als sie waren.
Fazit. Ein prozedurales Bias beim Design und 
bei der Interpretation von randomisierten 
Studien hat zu einem weit verbreiteten Ver-
lust geführt: Es wird nicht mehr verstanden, 
wie sich das Outcome bei Karotisstenose op-
timieren lässt. Der kumulative Einfluss die-
ses Bias spiegelt sich wider in aktuellen Leit-
linien, sie stellen also einen optimalen Aus-
gangspunkt für Ansätze zur Verbesserung der 
Prävention von apoplektischen Insulten und 
anderen Komplikationen von Gefäßerkran-
kungen dar. Allerdings bedarf dieser Prozess 
auch der Unterstützung von Klinikern, poli-
tisch Verantwortlichen, Kostenträgern und 
Weiterbildungseinrichtungen in der Gesund-
heitsversorgung sowie von der Öffentlichkeit.
Schlüsselwörter
Randomisierte Studie · Bias · Karotisstenose · 
Schlaganfallprävention · Evidenz
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Bias interpretation of 
randomized trials
Assume one or two randomized 
trials are enough (even if different)
Only one trial involving 825 surgical-
ly managed patients (randomized 1988–
1993) has shown that CEA may reduce 
the overall rate of ipsilateral stroke in pa-
tients with > 50 % ACS [18].  ACST is the 
only other randomized trial used to sup-
port this CEA stroke prevention benefit 
[19, 20]. The ACST was different to ACAS 
with respect to target patient population, 
randomized treatment arms and outcome 
measures; nevertheless, these studies have 
been the basis of guideline recommenda-
tions for CEA (and subsequently CAS) for 
50–99 % ACS in any place or time since 
the mid-1990s. However, despite continu-
ing guideline adherence to these trial re-
sults, clearly they have not been enough to 
determine best practice since ACAS and 
ACST results were often not replicated 
in routine practice (highlighting the im-
portance of quality local registry data) [5, 
24] and they were outdated long ago due 
to improvements in medical and surgical 
outcomes [1–3, 28–30, 40]. For the same 
reasons, clearly NASECT and ECST have 
not been enough to determine best prac-
tice for SCS patients. Quality local registry 
data and repeated measures of outcomes 
with medical treatment alone plus/minus 
additional procedures are required.
Confuse safety and 
efficacy outcomes
The CREST-1 trial [14] has been the main 
driver of recent recommendations in some 
guidelines that CAS is a suitable (even 
equivalent [32]) alternative to CEA in pa-
tients with ACS and/or SCS. In CREST-1, 
among all 2502 mixed symptomatic and 
asymptomatic patients, CAS was not as 
effective as CEA because it caused nearly 
twice as many strokes as CEA within the 
30-day post-procedural period with a haz-
ard ratio (HR) of 1.8 and 95 % confidence 
interval (CI) of 1.1–2.8 (P = 0.01). The first 
30 days following a procedure is the pe-
riod of highest risk for procedure-associ-
ated adverse events and where significant 
treatment differences most often appear. 
In CREST-1 the CAS-related stroke excess 
was still evident in 4 years at study end 
(HR 1.4, CI 1.0–2.1, P = 0.049), particular-
ly if periprocedural death was included 
(HR 1.5, CI 1.1–2.2, P = 0.03) [14]; howev-
er, in CREST-1 myocardial infarction (an 
adverse or safety outcome) was used in a 
balancing act to show no ‘statistically’ sig-
nificant difference between CAS and CEA 
in the chosen primary outcome measure 
(30-day periprocedural stroke, death or 
myocardial infarction or any ipsilateral 
stroke within 4 years of randomization) 
[14]. As well documented, in CREST-1, 
among all 2502 mixed symptomatic and 
asymptomatic patients, periprocedural 
clinically defined myocardial infarction 
was twice as common with CEA than CAS 
(28 versus 14 myocardial infarctions) [9, 
14]. However, periprocedural stroke was 
nearly twice (1.9 times) as common as 
periprocedural clinically defined myocar-
dial infarction (81 strokes versus 42 myo-
cardial infarctions) and approximately 1.3 
times as common as myocardial infarc-
tion defined clinically or with biomarker 
change only (81 strokes versus 62 myocar-
dial infarctions) [9, 14]. Because peripro-
cedural stroke was more common than 
periprocedural myocardial infarction in 
CREST-1, CAS still caused more of these 
clinically defined adverse outcomes than 
CEA (66 versus 57), although this did not 
reach statistical significance (HR 1.2, 95 % 
CI 0.8–1.7, P = 0.38) [14]. The incidence of 
myocardial infarction beyond the 30-day 
periprocedural period was not reported 
[9, 14].
In randomized trials of CAS versus 
CEA, where both 30-day periprocedur-
al outcomes were reported, stroke (most 
caused by CAS) was overall approximate-
ly 4.5 times as common as periprocedur-
al clinically defined myocardial infarction 
[12, 14–16, 22, 26]. A meta-analysis of all 
available randomized trials of CAS ver-
sus CEA (providing larger patient num-
bers than in CREST-1 alone) demonstrat-
ed among symptomatic patients a statisti-
cally significant higher risk of 30-day peri-
procedural stroke, death or myocardial in-
farction with CAS (odds ratio, OR 1.44, 
95 % CI 1.15–1.80, P = 0.002) [11], while 
the rate of ipsilateral stroke after the peri-
procedural period did not differ between 
treatments (OR 0.93, 95 % CI 0.60–1.45, 
P = 0.76) [11].
No randomized trial has been suffi-
ciently powered to test for a difference in 
rate of stroke with or without myocardial 
infarction in ACS patients alone; howev-
er, the direction of effect in CREST-1 (larg-
est relevant randomized trial) was indic-
ative of approximately double the rate 
with CAS (HR 1.86, 95 % CI 0.95–3.66, 
P = 0.07), similar to that of SCS patients 
[14]. Adverse outcomes, such as myocar-
dial infarction are a safety indicator and 
should not be confused with efficacy indi-
cators because this can camouflage treat-
ment differences and add to an inappro-
priate procedural bias, as has occurred 
with the reporting of CREST-1 and other 
studies [26, 42].
Assume randomized trial 
results apply to all patients
Using ACAS and ACST results, CEA re-
duced the overall average annual stroke 
rate by 0.5–1.0 % [18–20] despite a 30-day 
stroke or death rate of about 2.5 %. Howev-
er, as mentioned, a benefit for women was 
not seen in ACAS [18] or ACST at 5 years 
[20] and was of borderline statistical sig-
nificance in women younger than 75 years 
in ACST at 10 years [19]. Furthermore, a 
CEA benefit for men with ACS aged over 
75–79 years or women over 75 years has 
not been established [18–20]. Using the 
combined results of the randomized tri-
als of CEA versus medical treatment alone 
in patients with > 70 % SCS, CEA reduced 
the average annual rate of ipsilateral stroke 
by 3% despite a 30-day stroke or death 
rate of approximately 7 % [36]. Howev-
er, those men with index symptoms with-
in the previous 2 weeks, those with a life 
expectancy > 3 years and patients over 75 
years were most likely to benefit [36–38]. 
Furthermore, there is no randomized tri-
al evidence that CAS benefits any patients 
with ACS or SCS, only evidence of over-
all harm; however, international guide-
lines often endorse CEA and/or CAS for 
just about all patients with carotid steno-
sis over 50–70 %, instead of limiting en-
dorsements to subgroups shown to ben-
efit (Systematic Review of Guidelines for 
the Management of Asymptomatic and 
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Symptomatic Carotid Stenosis, Abbott et 
al. in preparation).
Discount non-randomized data
Randomized trials are not always possible 
or the most appropriate way to address a 
clinical question. They may even be un-
ethical, as indicated previously. Quali-
ty non-randomized trial data (including 
from quality registries) should determine 
the need for randomized trials and en-
sure favored randomized trial results are 
at least as good in routine practice. Non-
randomized studies, therefore, should be 
the ‘work-horse’ of the evidence base, re-
serving randomized studies for situations 
where there is real uncertainty and rea-
sonable comparisons to be made. If non-
randomized study data are considered in-
ferior, the goal is to improve rather than 
dismiss them [6].
Contemporary guidelines place far 
too much emphasis on the presence of 
randomization and not enough on oth-
er relevant issues, such as how well the 
study sample is described and how rele-
vant it is to the clinical question; whether 
or not target populations are adequately 
defined or all reasonable treatment strat-
egies were compared and described ade-
quately; whether or not treatment strate-
gies were current, optimal and adhered to; 
whether or not the main outcome mea-
sure was related to efficacy or safety and 
if it was appropriate for the clinical ques-
tion; whether or not any treatment differ-
ences were clinically meaningful (rath-
er than statistically significant); whether 
the study methods were practical or can 
be replicated in routine practice, whether 
or not results have been adequately vali-
dated and the extent to which investigator 
income was dependent on the study re-
sults. Guideline writers need to recognize 
the complimentary power of randomized 
and non-randomized data and the limita-
tions they may share.
Conclusions
Randomized trials are a subset of pro-
spective, observational cohort studies in 
which patients are ‘randomized’ to two 
or more possible treatment strategies. As 
explained previously, they are subject to 
the same limitations as non-randomized 
trials, including bias in patient selection, 
treatment allocation and result interpre-
tation. Randomization cannot correct 
for all these potential problems and is 
not usually the best approach to answer 
a clinical question. The relative dismiss-
al of medical treatment in the manage-
ment of carotid stenosis and bias in favor 
of unhelpful procedures has occurred be-
cause of overreliance on the relevance of 
randomized trial data. There is an urgent 
need for guideline writers to address 
this and update and otherwise improve 
their recommendations.
In addition, there are likely to be wid-
er influences that encourage a proce-
dural bias in carotid stenosis manage-
ment, such as the way medical services 
are funded. A procedural bias may be en-
couraged where there is a proportionally 
higher reimbursement for time perform-
ing procedures rather than spent in valu-
able communication with patients and 
others to facilitate accurate diagnosis 
and best treatment. Furthermore, medi-
cal funding has been ‘activity’ rather than 
patient outcome focused for too long. 
Funders of health services (including es-
pecially governments) need to become 
more responsible and fund what works 
to improve patient outcomes, stop pay-
ing for what does not and fund the re-
search to tell the difference.
There is a tremendous need for clini-
cians everywhere to systematically mea-
sure key outcomes of the treatment they 
give patients, whether or not it is pro-
cedural. This could be much more easi-
ly achieved if doctors’ records were elec-
tronic and standardized with respect to 
topics covered and crucial terminolo-
gy used so that the information could be 
used for two purposes: immediate pa-
tient care (medical reports generation) 
and care improvement through health 
services research (registries) [6]. Doctors 
who don’t count, don’t count [8]. The sit-
uation is urgent with government spend-
ing on health services growing unsus-
tainably [27, 34], while salaries for even 
the ‘best’ independent international clin-
ical researchers are nearly impossible 
to secure, even for a short time. Final-
ly, there is a great need to educate chil-
dren before they leave school about how 
to recognize complications of highly pre-
ventable conditions, such as atheroscle-
rosis and understand the great effective-
ness of them adopting a healthy lifestyle 
and appropriate use of medication.
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